Form D · Other Health Care
ENZO BIOCHEM INC
Farmingdale, NY · CIK 0000316253
Offering snapshot reported Jun 5, 2023 · SEC filing
- Reported sold
- $7M Offering amount: $7M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 19, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 5, 2023 | Initial | $7,000,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-483263
Source: Form D, filed Jun 5, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kara Cannon | Executive |
| Patricia Eckert | Executive |
| Hamid Erfanian | Director, Executive |
| Matthew Kupferberg | Executive |
| Elazar Rabbani, Ph.D. | Director |
| Bradley L. Radoff | Director |
| Dieter Schapfel, M.D. | Executive |
| Mary Tagliaferri, M.D. | Director |
| Ian Walters, M.D. | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
81 Executive Blvd., Suite 3
Farmingdale, NY, 11735
Farmingdale, NY, 11735